This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Case report
Endocardial radiofrequency septal ablation for hypertrophic obstructive cardiomyopathy:two case reports
Feng Xiong
Corresponding Author
ORCiD: https://orcid.org/0000-0002-5231-201X
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Endocardial radiofrequency ablation of the septal hypertrophy (ERASH) is an alternative for hypertrophic obstructive cardiomyopathy (HOCM). Radiofrequency ablation could lead to regional myocardial akinesia, so as to relieve the left ventricular outflow tract (LVOT) gradient. We reported that two patients presented Left ventricular asymmetric hypertrophy in transthoracic echocardiography, and were diagnosed with HOCM. One had a gradient up to 210mmHg during the provocation. The other had a gradient of LVOT up to 108mmHg at rest. Both are symptomatic despite of the optimized medication. Due to the restriction of coronary anatomy, the patients lost the opportunity for the alcohol septal ablation (ASA). ERASH is programmed. The target site was determined by intracardial echocardiography and electroanatomic Carto-mapping system. ERASH caused the targeted myocardium hypokinesia precisely, aiming for interdicting mitral valve systolic anterior motion. 1-month follow-up showed a remarkable improvement of clinical state and a predominant reduction of LVOT gradient assessing by transthoracic echocardiography. ERASH comes up with a new solution for the patient who is not candidate for ventricular septal myectomy and ASA. Carto-mapping system and intracardiac echocardiography enable precise lesion placement and preservation of atrioventricular conduction.
Keywords
Endocardial radiofrequency ablation of the septal hypertrophy, hypertrophic obstructive cardiomyopathy
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 14 Jan, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cardiac & Cardiovascular Systems
Learn more about our company.
This is a preprint. It has not completed peer review.
Case report
Endocardial radiofrequency septal ablation for hypertrophic obstructive cardiomyopathy:two case reports
Feng Xiong
Corresponding Author
ORCiD: https://orcid.org/0000-0002-5231-201X
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 14 Jan, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cardiac & Cardiovascular Systems
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Endocardial radiofrequency ablation of the septal hypertrophy (ERASH) is an alternative for hypertrophic obstructive cardiomyopathy (HOCM). Radiofrequency ablation could lead to regional myocardial akinesia, so as to relieve the left ventricular outflow tract (LVOT) gradient. We reported that two patients presented Left ventricular asymmetric hypertrophy in transthoracic echocardiography, and were diagnosed with HOCM. One had a gradient up to 210mmHg during the provocation. The other had a gradient of LVOT up to 108mmHg at rest. Both are symptomatic despite of the optimized medication. Due to the restriction of coronary anatomy, the patients lost the opportunity for the alcohol septal ablation (ASA). ERASH is programmed. The target site was determined by intracardial echocardiography and electroanatomic Carto-mapping system. ERASH caused the targeted myocardium hypokinesia precisely, aiming for interdicting mitral valve systolic anterior motion. 1-month follow-up showed a remarkable improvement of clinical state and a predominant reduction of LVOT gradient assessing by transthoracic echocardiography. ERASH comes up with a new solution for the patient who is not candidate for ventricular septal myectomy and ASA. Carto-mapping system and intracardiac echocardiography enable precise lesion placement and preservation of atrioventricular conduction.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5